ImmunityBio received Expanded Access authorization from the FDA on June 25, 2025.
1 report, 0 independent
Updated Jun 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ImmunityBio received Expanded Access authorization from the FDA on June 25, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
ImmunityBio
biotech company
Nothing else this week.
- FDA
Related events
- ImmunityBio and Editas Medicine are competing for investment funding as healthcare companies.
- Immuneering submitted a meeting request to the FDA regarding its therapies.
- The FDA aligned vaccine formulas with global health recommendations provided by the World Health Organization.
- An FDA decision influenced AbCellera's stock climb, related to the company's work advancing immune treatments.
- FDA granted approval for Pfizer's updated vaccine on September 2, 2025.
Coverage
Newest first; wire copies grouped- Unknown outlet